Prescribing patterns in older people with advanced chronic kidney disease towards the end of life
M Letts(North Bristol NHS Trust), Sandra Biribauer, Nicholas C Chesnaye(Amsterdam Neuroscience), Hans Schmidt-Gürtler, Christian Marx, Kai Hahn, Justyna Mazur, Ines Schlee, Sabine Aign, Kirsten Anding‐Rost, Katja Blouin, Holger Naujoks, Christoph Wanner(Universitätsklinikum Würzburg), Eva Platen, Marie Evans(Karolinska University Hospital), Monika Hopf, Antonio Vilasi(IFC Research (United Kingdom)), Pawlos Ichtiaris, Kitty J. Jager(Amsterdam University Medical Centers), Katrin Neumeier, Christiane Drechsler(Universitätsklinikum Würzburg), Petra Kirste, Sabine Cäsar, Nikolaus Frischmuth, Jochen Röthele, Petra Schulz, Hendrik Schlee, Boris Perras, Dunja Fuchs, Barnaby Hole(North Bristol NHS Trust), Beate Iwig, Joachim Beige, Nadja Wuttke, Maciej Szymczak(Wroclaw Medical University), Samantha Hayward(University of Bristol), Friedo W. Dekker(Leiden University Medical Center), Fergus Caskey, Claudia Emde, Maria Pippias(North Bristol NHS Trust), Christof Blaser, Detlef H. Krieter(Universitätsklinikum Würzburg), Andreas Schneider, Merel van Diepen(Leiden University Medical Center), Claudia Torino(National Academies of Sciences, Engineering, and Medicine), Ellen Irmler, Lothar Schramm, Anke Torp
Cited by 2
Related Papers
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|1k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990
A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases
|Kidney International|2019|886
An introduction to inverse probability of treatment weighting in observational research
|Clinical Kidney Journal|2021|877